New Benchmarks Characterizing Growth in Protocol Design Complexity
Authors:
- 1 January 2018
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 52 (1) , 22-28
Abstract
The Tufts Center for the Study of Drug Development and Medidata Solutions Inc analyzed data from 9737 protocols and 130,601 investigative site contracts associated with these protocols to derive updated benchmarks characterizing protocol complexity. The results of the study indicate that protocol design complexity continues to grow rapidly. Nearly all phase I, II, and III complexity measures associated with protocol execution increased significantly (eg, P < .0001) from 2001-2005 to 2011-2015. These measures include the number of unique and total procedures performed per patient over the course of a study, the site work effort to administer protocol procedures, the number of study volunteer visits, and the total number of procedures performed per study volunteer visit. The total cost per planned study volunteer per visit also increased significantly (eg, P < .0001) as did the total cost per study volunteer across all planned study visits. Phase I protocols remain the most complex and the most demanding to execute. Phase III protocols have seen the most substantial growth in protocol complexity. Phase IV protocols saw only modest increases in executional complexity during the 10-year time horizon. The implications of the study findings are discussed.Keywords
This publication has 12 references indexed in Scilit:
- Quantifying the Magnitude and Cost of Collecting Extraneous Protocol DataAmerican Journal of Therapeutics, 2015
- What Makes a Good Protocol Better?2015
- New Governance Mechanisms to Optimize Protocol DesignTherapeutic Innovation & Regulatory Science, 2013
- Data Collection and Quality Control2010
- Assessing the Impact of Protocol Design Changes on Clinical Trial PerformanceAmerican Journal of Therapeutics, 2008
- Quantifying Data Quality for Clinical Trials Using Electronic Data CapturePLOS ONE, 2008
- Factors associated with early study discontinuation in AACTG studies, DACS 200Contemporary Clinical Trials, 2007
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Use of Physicians' Services under Medicare's Resource-Based PaymentsNew England Journal of Medicine, 2007
- Barriers to Participation in Randomised Controlled TrialsJournal of Clinical Epidemiology, 1999